TY - JOUR
T1 - Isolated lymph node relapse of epithelial ovarian carcinoma
T2 - Outcomes and prognostic factors
AU - Blanchard, Pierre
AU - Plantade, Anne
AU - Pagès, Cécile
AU - Afchain, Pauline
AU - Louvet, Christophe
AU - Tournigand, Christophe
AU - de Gramont, Aimery
PY - 2007/1/1
Y1 - 2007/1/1
N2 - Background: Relapses of epithelial ovarian carcinoma (EOC) have a poor prognosis. Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy. Methods: This retrospective study aimed to describe incidence, characteristics, outcomes and prognostic factors of ILNR treated over 15 years. Results: Twenty-seven patients (4.2%) experienced an ILNR among 640 patients. Median age was 59 years, tumour stages included stage I (n = 4), II (n = 5), III (n = 15) and IV (n = 3). After initial optimal treatment, median progression-free survival (PFS) was 26 months. Sites of relapse were retroperitoneum (n = 15), left supraclavicular (n = 7), mediastinum (n = 4), iliac (n = 4) and inguinal (n = 3). ILNR locations were unique in 63% of patients (n = 17) and multiple in 37% (n = 10). Treatment modalities were surgery in eight patients (30%), chemotherapy in 15 (55%) and radiotherapy in 5 patients (18%), alone or in combination. Seven patients without tumour-related symptoms (26%) were not treated. Median overall survival (OS) after ILNR was 26 months. Median OS from initial diagnosis was 68 months. 25% of patients had a very long survival (> 100 months), independent of their initial staging or PFS. There was no difference in 2-year survival after ILNR between the groups of early relapse (before 24 months) and late relapse (after 24 months). In the seven non-treated patients, median OS was 91 months. Conclusion: ILNR is a rare event in EOC. Time to relapse may not have its usual prognostic value. Immediate or delayed therapy should be discussed in case of asymptomatic ILNR.
AB - Background: Relapses of epithelial ovarian carcinoma (EOC) have a poor prognosis. Isolated lymph node relapses (ILNR) are considered of relatively good prognosis with intensive therapy. Methods: This retrospective study aimed to describe incidence, characteristics, outcomes and prognostic factors of ILNR treated over 15 years. Results: Twenty-seven patients (4.2%) experienced an ILNR among 640 patients. Median age was 59 years, tumour stages included stage I (n = 4), II (n = 5), III (n = 15) and IV (n = 3). After initial optimal treatment, median progression-free survival (PFS) was 26 months. Sites of relapse were retroperitoneum (n = 15), left supraclavicular (n = 7), mediastinum (n = 4), iliac (n = 4) and inguinal (n = 3). ILNR locations were unique in 63% of patients (n = 17) and multiple in 37% (n = 10). Treatment modalities were surgery in eight patients (30%), chemotherapy in 15 (55%) and radiotherapy in 5 patients (18%), alone or in combination. Seven patients without tumour-related symptoms (26%) were not treated. Median overall survival (OS) after ILNR was 26 months. Median OS from initial diagnosis was 68 months. 25% of patients had a very long survival (> 100 months), independent of their initial staging or PFS. There was no difference in 2-year survival after ILNR between the groups of early relapse (before 24 months) and late relapse (after 24 months). In the seven non-treated patients, median OS was 91 months. Conclusion: ILNR is a rare event in EOC. Time to relapse may not have its usual prognostic value. Immediate or delayed therapy should be discussed in case of asymptomatic ILNR.
KW - Chemotherapy
KW - Lymph node relapse
KW - Natural history
KW - Ovarian carcinoma
KW - Spontaneous remission
UR - http://www.scopus.com/inward/record.url?scp=33846018958&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2006.06.039
DO - 10.1016/j.ygyno.2006.06.039
M3 - Article
C2 - 16952391
AN - SCOPUS:33846018958
SN - 0090-8258
VL - 104
SP - 41
EP - 45
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -